News & Views
Key Appointment Set to Build Leadership in Gene Editing
May 30 2018 Read 493 Times
Terry Pizzie has been appointed as Horizon Discovery Group’s Chief Executive Officer and Board Director. As Head of Commercial Operations since joining the company in 2017, Terry has rapidly built a world-class commercial team, focused on providing the company’s full portfolio across different geographies, as well as forming teams concentrating on adding value to key customer accounts, said the company.
Prior to joining Horizon, Terry worked for Pacific Biosciences, first as Vice President Europe and later as Head of Global Sales. Previous leadership roles include Director Global Commercial Operations at Genetix prior to its acquisition by Danaher; and Senior Vice President Global Commercial Operations at Swedish Biotechnology firm Biacore, where he was part of the team that reignited the company's commercial success, culminating in its acquisition by GE Life Sciences in 2006. Terry started his career at Applied Biosystems in 1988 in a sales role and rose through the ranks to Vice President Europe in 2003. Terry graduated with a degree in Physiology & Biochemistry from the University of Reading.
Terry Pizzie, said: "Horizon has built a highly successful global business which has a world leading position in gene editing and gene modulation. We are now an established market leader across the high value and high margin RNAi and CRISPR end-markets which are estimated to be worth £2.2 billion and growing at approximately 20% per year. The Company is also a technology leader in the broader field of cell engineering as evidenced by the commercial success with important customers in this field. I am honoured to have been appointed to lead the Group at such an important stage in the Company's development. With the strong product and commercial platforms in place and our presence in high-growth markets I look forward to working with the Board and executive management team to deliver on our vision and strategy to build value for our customers, patients and shareholders."
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - VMXm takes its First Users 'wher...
View all digital editions
May 26 2019 Helsinki, Finland
Jun 02 2019 Atlanta, GA, USA
Jun 10 2019 Berlin, Germany
Jun 12 2019 Shanghai, China
Jun 16 2019 Milan, Italy